These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 17976003)
41. Novel aminopeptidase N inhibitors derived from antineoplaston AS2-5 (Part I). Li X; Wang J; Li J; Wu J; Li Y; Zhu H; Fan R; Xu W Bioorg Med Chem; 2009 Apr; 17(8):3053-60. PubMed ID: 19329328 [TBL] [Abstract][Full Text] [Related]
42. Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings. Chen KX; Vibulbhan B; Yang W; Nair LG; Tong X; Cheng KC; Njoroge FG Bioorg Med Chem Lett; 2009 Feb; 19(4):1105-9. PubMed ID: 19168351 [TBL] [Abstract][Full Text] [Related]
43. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus. Tsantrizos YS Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464 [TBL] [Abstract][Full Text] [Related]
44. Pharmacophore-guided lead optimization: the rational design of a non-zinc coordinating, sub-micromolar inhibitor of the botulinum neurotoxin serotype a metalloprotease. Burnett JC; Wang C; Nuss JE; Nguyen TL; Hermone AR; Schmidt JJ; Gussio R; Wipf P; Bavari S Bioorg Med Chem Lett; 2009 Oct; 19(19):5811-3. PubMed ID: 19703771 [TBL] [Abstract][Full Text] [Related]
45. The P1N-isopropyl motif bearing hydroxyethylene dipeptide isostere analogues of aliskiren are in vitro potent inhibitors of the human aspartyl protease renin. Yamaguchi Y; Menear K; Cohen NC; Mah R; Cumin F; Schnell C; Wood JM; Maibaum J Bioorg Med Chem Lett; 2009 Aug; 19(16):4863-7. PubMed ID: 19615901 [TBL] [Abstract][Full Text] [Related]
46. Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs). Zhang YM; Fan X; Yang SM; Scannevin RH; Burke SL; Rhodes KJ; Jackson PF Bioorg Med Chem Lett; 2008 Jan; 18(1):405-8. PubMed ID: 17980583 [TBL] [Abstract][Full Text] [Related]
47. Phosphorous acid analogs of novel P2-P4 macrocycles as inhibitors of HCV-NS3 protease. Pompei M; Francesco ME; Koch U; Liverton NJ; Summa V Bioorg Med Chem Lett; 2009 May; 19(9):2574-8. PubMed ID: 19328685 [TBL] [Abstract][Full Text] [Related]
48. Design and synthesis of 4-quinolinone 2-carboxamides as calpain inhibitors. Nam DH; Lee KS; Kim SH; Kim SM; Jung SY; Chung SH; Kim HJ; Kim ND; Jin C; Lee YS Bioorg Med Chem Lett; 2008 Jan; 18(1):205-9. PubMed ID: 18024028 [TBL] [Abstract][Full Text] [Related]
49. Rhodanine derivatives as selective protease inhibitors against bacterial toxins. Johnson SL; Chen LH; Harbach R; Sabet M; Savinov A; Cotton NJ; Strongin A; Guiney D; Pellecchia M Chem Biol Drug Des; 2008 Feb; 71(2):131-9. PubMed ID: 18221310 [TBL] [Abstract][Full Text] [Related]
50. A double WAP domain (DWD)-containing protein with proteinase inhibitory activity in Chinese white shrimp, Fenneropenaeus chinensis. Du ZQ; Ren Q; Zhao XF; Wang JX Comp Biochem Physiol B Biochem Mol Biol; 2009 Oct; 154(2):203-10. PubMed ID: 19545640 [TBL] [Abstract][Full Text] [Related]
51. Identification of acridinyl hydrazides as potent aspartic protease inhibitors. Azim MK; Ahmed W; Khan IA; Rao NA; Khan KM Bioorg Med Chem Lett; 2008 May; 18(9):3011-5. PubMed ID: 18417344 [TBL] [Abstract][Full Text] [Related]
53. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques. Wei HY; Lu CS; Lin TH J Mol Graph Model; 2008 Apr; 26(7):1131-44. PubMed ID: 18024210 [TBL] [Abstract][Full Text] [Related]
54. Design and synthesis of potent amido- and benzyl-substituted cis-3-amino-4-(2-cyanopyrrolidide)pyrrolidinyl DPP-IV inhibitors. Corbett JW; Dirico K; Song W; Boscoe BP; Doran SD; Boyer D; Qiu X; Ammirati M; Vanvolkenburg MA; McPherson RK; Parker JC; Cox ED Bioorg Med Chem Lett; 2007 Dec; 17(24):6707-13. PubMed ID: 17977724 [TBL] [Abstract][Full Text] [Related]
55. Scalarane-based sesterterpenoid RCE-protease inhibitors isolated from the Indonesian marine sponge Carteriospongia foliascens. Williams DE; Hollander I; Feldberg L; Frommer E; Mallon R; Tahir A; van Soest R; Andersen RJ J Nat Prod; 2009 Jun; 72(6):1106-9. PubMed ID: 19485329 [TBL] [Abstract][Full Text] [Related]
56. Synthesis, SAR, and X-ray structure of human BACE-1 inhibitors with cyclic urea derivatives. Park H; Min K; Kwak HS; Koo KD; Lim D; Seo SW; Choi JU; Platt B; Choi DY Bioorg Med Chem Lett; 2008 May; 18(9):2900-4. PubMed ID: 18434152 [TBL] [Abstract][Full Text] [Related]
57. Beta-amino acid substitutions and structure-based CoMFA modeling of hepatitis C virus NS3 protease inhibitors. Nurbo J; Peterson SD; Dahl G; Helena Danielson U; Karlén A; Sandström A Bioorg Med Chem; 2008 May; 16(10):5590-605. PubMed ID: 18434166 [TBL] [Abstract][Full Text] [Related]
58. Development of a receptor-based 3D-QSAR study for the analysis of MMP2, MMP3, and MMP9 inhibitors. Tuccinardi T; Nuti E; Ortore G; Rossello A; Avramova SI; Martinelli A Bioorg Med Chem; 2008 Aug; 16(16):7749-58. PubMed ID: 18640045 [TBL] [Abstract][Full Text] [Related]
59. Towards the control of intracellular protein turnover: mitochondrial Lon protease inhibitors versus proteasome inhibitors. Bayot A; Basse N; Lee I; Gareil M; Pirotte B; Bulteau AL; Friguet B; Reboud-Ravaux M Biochimie; 2008 Feb; 90(2):260-9. PubMed ID: 18021745 [TBL] [Abstract][Full Text] [Related]